| | ctrl | Without FBS | csf-1r siRNA | Non-coding siRNA | CSF-1 25 ng/ml | CSF-1 50 ng/ml | CSF-1 100 ng/ml |
|---|
CMT-U27 | 72.10 | 73.4 | 15.65*** | 75.80 | 99.85*** | 99.80*** | 99.65*** |
CMT-U309 | 66.80 | 70.0 | 3.00*** | 64.40 | 99.75* | 99.85* | 99.65* |
P114 | 88.70 | 73.7 | 38,45*** | 90.85 | 99.80* | 99.80* | 99.90* |
CMT-W1 | 80.45 | 73.6 | 23.45*** | 82.30 | 99.55** | 99.55** | 99.75** |
CMT-W2 | 58.70 | 52.3 | 23.15*** | 64.80 | 99.35*** | 99.10*** | 99.55*** |
- The number of CSF-1R expressing cells obtained with FACS Aria II (Becton Dickinson). The number of cells which express CSF-1R is significantly decreased after the csf-1r specific siRNA treatment and significantly increased after treatment with CSF-1 at the dose of 25, 50 and 100 ng/ml (no significant differences between these doses have been observed). Treatment of cells with non-coding siRNA did not cause any effect. The experiment has been conducted in three replicates. P<0.05 was regarded as significant and marked as *, whereas p<0.01 and p<0.001 was regarded as highly significant and marked as * and ***, respectively. One-way ANOVA followed by Tukey HSD post-hoc test were applied.
